Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

NCT04246021 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-01-04

Study results available
· View outcomes & findings →

Summary

This study is a nonrandomized, single arm, open-label study stratified by iron-deficiency status.

Conditions

Interventions

DRUG

Ferric carboxymaltose (FCM)

intravenous iron formulation

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    collaborator INDUSTRY
  • King Hussein Cancer Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-15
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04246021 on ClinicalTrials.gov